ArticleBlood advances2025

Hematopoietic progenitor kinase-1 inhibition improves the in vitro efficacy of bispecific antibodies in CLL.

Yamit Shorer Arbel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.